EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Empagliflozin in Patients with Chronic Kidney Disease

The EMPA-KIDNEY Collaborative Group, William G Herrington iD, Natalie Staplin, Christoph Wanner, Jennifer B Green, Sibylle J Hauske, Jonathan R Emberson, David Preiss, Parminder Judge, Kaitlin J Mayne, Sarah Y A Ng, Emily Sammons und 28 weitere

New England Journal of Medicine · 12.01.2023 · 388 (2) · 117-127

DOI: 10.1056/nejmoa2204233 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 12.01.2023. Verfasst von The EMPA-KIDNEY Collaborative Group und 39 weiteren Autor:innen. Beteiligte Einrichtung: The affiliations of the members of the writing committee are as follows: the Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield D…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 2704-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: British Heart Foundation, Medical Research Council, Kidney Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesDiabetes Mellitus, Type 2Renal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsHumansBenzhydryl CompoundsCreatinineDisease ProgressionGlomerular Filtration RateKidneyGlucosides

Substanzen

Benzhydryl CompoundsCreatinineSodium-Glucose Transporter 2 InhibitorsempagliflozinGlucosides

Autor:innen und Institutionen

  • The affiliations of the members of the writing committee are as follows: the Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (W.G.H., N.S., J.R.E., D.P., P.J., K.J.…

ORCID-Profile: William G Herrington, Katherine R Tuttle, Martin J Landray

Förderung

  • British Heart Foundation
  • Medical Research Council
  • Kidney Research UK
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • NIHR Biomedical Centre, Oxford
  • Health Data Research

Zitieren

APA

The EMPA-KIDNEY Collaborative Group, Herrington, W. G., Staplin, N., Wanner, C., Green, J. B., Hauske, S. J., Emberson, J. R., Preiss, D., Judge, P., Mayne, K. J., Ng, S. Y. A., Sammons, E., Zhu, D., Hill, M., Stevens, W., Wallendszus, K., Brenner, S., Cheung, A. K., Liu, Z. H., …, & Haynes, R. (2023). Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 388(2), 117-127. https://doi.org/10.1056/nejmoa2204233

Vancouver

The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2023;388(2):117-127. doi:10.1056/nejmoa2204233

BibTeX
@article{TheEMPAKIDNEYCollaborativeGroup2023,
  author = {The EMPA-KIDNEY Collaborative Group, The EMPA-KIDNEY Collaborative Group and Herrington, William G and Staplin, Natalie and Wanner, Christoph and Green, Jennifer B and Hauske, Sibylle J and Emberson, Jonathan R and Preiss, David and Judge, Parminder and Mayne, Kaitlin J and Ng, Sarah Y A and Sammons, Emily and Zhu, Doreen and Hill, Michael and Stevens, Will and Wallendszus, Karl and Brenner, Susanne and Cheung, Alfred K and Liu, Zhi-Hong and Li, Jing and Hooi, Lai Seong and Liu, Wen and Kadowaki, Takashi and Nangaku, Masaomi and Levin, Adeera and Cherney, David and Maggioni, Aldo P and Pontremoli, Roberto and Deo, Rajat and Goto, Shinya and Rossello, Xavier and Tuttle, Katherine R and Steubl, Dominik and Petrini, Michaela and Massey, Dan and Eilbracht, Jens and Brueckmann, Martina and Landray, Martin J and Baigent, Colin and Haynes, Richard},
  title = {Empagliflozin in Patients with Chronic Kidney Disease},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {2},
  pages = {117--127},
  doi = {10.1056/nejmoa2204233}
}
Kostenlos starten →